These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 24131964)
61. miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype. Tommasi S; Pinto R; Danza K; Pilato B; Palumbo O; Micale L; De Summa S Oncotarget; 2016 Dec; 7(49):80363-80372. PubMed ID: 27385001 [TBL] [Abstract][Full Text] [Related]
62. Evaluation of the methods to identify patients who may benefit from PARP inhibitor use. Lim D; Ngeow J Endocr Relat Cancer; 2016 Jun; 23(6):R267-85. PubMed ID: 27226207 [TBL] [Abstract][Full Text] [Related]
63. BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer. Pothuri B Ann Oncol; 2013 Nov; 24 Suppl 8():viii22-viii27. PubMed ID: 24131965 [TBL] [Abstract][Full Text] [Related]
64. BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane. Ishikawa T; Narui K; Tanabe M; Kida K; Oba MS; Yamada A; Ichikawa Y; Endo I Eur J Surg Oncol; 2016 Jul; 42(7):999-1001. PubMed ID: 27041672 [TBL] [Abstract][Full Text] [Related]
65. Hereditary breast cancer: part II. Management of hereditary breast cancer: implications of molecular genetics and pathology. Silva E; Gatalica Z; Snyder C; Vranic S; Lynch JF; Lynch HT Breast J; 2008; 14(1):14-24. PubMed ID: 18086271 [TBL] [Abstract][Full Text] [Related]
66. CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer. Plevova P; Cerna D; Balcar A; Foretova L; Zapletalova J; Silhanova E; Curik R; Dvorackova J Neoplasma; 2010; 57(4):325-32. PubMed ID: 20429623 [TBL] [Abstract][Full Text] [Related]
67. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Anders CK; Carey LA Clin Breast Cancer; 2009 Jun; 9 Suppl 2(Suppl 2):S73-81. PubMed ID: 19596646 [TBL] [Abstract][Full Text] [Related]
68. Advances in PARP inhibitors for the treatment of breast cancer. Dizdar O; Arslan C; Altundag K Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111 [TBL] [Abstract][Full Text] [Related]
69. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers. Aleskandarany M; Caracappa D; Nolan CC; Macmillan RD; Ellis IO; Rakha EA; Green AR Breast Cancer Res Treat; 2015 Feb; 150(1):81-90. PubMed ID: 25690937 [TBL] [Abstract][Full Text] [Related]
70. Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer. Danzinger S; Tan YY; Rudas M; Kastner MT; Weingartshofer S; Muhr D; Singer CF BMC Cancer; 2019 Jul; 19(1):695. PubMed ID: 31307407 [TBL] [Abstract][Full Text] [Related]
71. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Bane AL; Beck JC; Bleiweiss I; Buys SS; Catalano E; Daly MB; Giles G; Godwin AK; Hibshoosh H; Hopper JL; John EM; Layfield L; Longacre T; Miron A; Senie R; Southey MC; West DW; Whittemore AS; Wu H; Andrulis IL; O'Malley FP Am J Surg Pathol; 2007 Jan; 31(1):121-8. PubMed ID: 17197928 [TBL] [Abstract][Full Text] [Related]
72. [Triple-negative breast cancer: molecular characteristics and potential therapeutic approaches]. Nowacka-Zawisza M; Krajewska WM Postepy Hig Med Dosw (Online); 2013 Nov; 67():1090-7. PubMed ID: 24379250 [TBL] [Abstract][Full Text] [Related]
73. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field. Yam C; Mani SA; Moulder SL Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413 [TBL] [Abstract][Full Text] [Related]
74. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Rodríguez-Pinilla SM; Sarrió D; Honrado E; Hardisson D; Calero F; Benitez J; Palacios J Clin Cancer Res; 2006 Mar; 12(5):1533-9. PubMed ID: 16533778 [TBL] [Abstract][Full Text] [Related]
75. Tailored targeted therapy for all: a realistic and worthwhile objective? Lønning PE Breast Cancer Res; 2009; 11 Suppl 3(Suppl 3):S7. PubMed ID: 20030882 [No Abstract] [Full Text] [Related]
76. Debate: tailored targeted therapy for all--a realistic and worthwhile objective? Introduction to Session 2. Smith IE Breast Cancer Res; 2009; 11 Suppl 3(Suppl 3):S6. PubMed ID: 20030881 [No Abstract] [Full Text] [Related]
77. Endogenous DNA 3' Blocks Are Vulnerabilities for BRCA1 and BRCA2 Deficiency and Are Reversed by the APE2 Nuclease. Álvarez-Quilón A; Wojtaszek JL; Mathieu MC; Patel T; Appel CD; Hustedt N; Rossi SE; Wallace BD; Setiaputra D; Adam S; Ohashi Y; Melo H; Cho T; Gervais C; Muñoz IM; Grazzini E; Young JTF; Rouse J; Zinda M; Williams RS; Durocher D Mol Cell; 2020 Jun; 78(6):1152-1165.e8. PubMed ID: 32516598 [TBL] [Abstract][Full Text] [Related]
78. Development of a novel BRCAness score that predicts response to PARP inhibitors. Oshi M; Gandhi S; Wu R; Asaoka M; Yan L; Yamada A; Yamamoto S; Narui K; Chishima T; Ishikawa T; Endo I; Takabe K Biomark Res; 2022 Nov; 10(1):80. PubMed ID: 36371386 [TBL] [Abstract][Full Text] [Related]
79. BRCAness of brain lesions reflects a worse outcome for patients with metastatic breast cancer. Ishizuka Y; Horimoto Y; Eguchi H; Murakami F; Nakai K; Onagi H; Hayashi T; Ishikawa T; Arai M; Watanabe J Breast Cancer Res Treat; 2024 Jan; 203(1):49-55. PubMed ID: 37728693 [TBL] [Abstract][Full Text] [Related]
80. Molecular Classification, Treatment, and Genetic Biomarkers in Triple-Negative Breast Cancer: A Review. Lu B; Natarajan E; Balaji Raghavendran HR; Markandan UD Technol Cancer Res Treat; 2023; 22():15330338221145246. PubMed ID: 36601658 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]